Entrada Therapeutics, co-founded by Dr. Pei in 2016, was recently launched publicly with $59M series A financing with best in-class biotech veterans/innovators and leading biotech investors. Entrada’s technology enables the intracellular delivery of cargo that are not cell-permeable using pioneering research from the Pei group. Congratulations Dehua! (Press Releases)